This study looks at how teens with trauma-related symptoms respond to stress and strong emotions. We will measure brain activity, body responses, and behavior during activities that involve reacting to possible threats, managing emotions, and imagining parts of their own stressful or traumatic experiences more than once.

The goal of this research is to better understand how repeating these imagining activities affects teens. We also want to learn whether a teen's reaction to stress and their ability to manage emotions are connected to how they respond to imagining stressful events.

What we learn may help improve treatments for posttraumatic stress disorder (PTSD) and help identify which teens are most likely to benefit from these treatments, based on brain, body, and behavior responses.

Quantitative survey of certain substances of abuse in the adolescent and young adult population of SC. Survey study will be focused on substances of abuse that are easily accessible at a gas station due to little to no regulations or excessive amounts available in various forms such as Kratom, 7-OH, Tia, nicotine pouches, THC, etc.

Written Exposure Therapy (WET) is a five-session mental health therapy for post-traumatic stress disorder (PTSD). Research shows that it works as well as longer treatments for PTSD among people over 18, even though it requires fewer sessions than other PTSD therapies. However, WET has not been adapted and formally tested in individual therapy with people aged 12 to 18. Our study aims to see how WET can be adapted to meet the needs of people aged 12 to 18 who have experienced trauma and currently have PTSD symptoms. To adapt WET for this age group, first we will talk with PTSD experts and people aged 12 to 18 to learn what changes might make WET more suitable for young people. We'll also deliver WET to five people aged 12 to 18 following the manual as it is written for people over age 18 to see what needs adjusting.

In the next part of the study, we will recruit 48 adolescents aged 12 to 18 in a pediatric primary clinic who have symptoms of PTSD and randomize them to either receive the adapted version of WET or to receive gold-standard PTSD treatment: Trauma-Focused Cognitive Behavior Therapy. If assigned to receive adapted WET, participants will take part in five to seven weekly therapy sessions and five study visits (before therapy, and 6-week, 10-week, 20-weeks, and 30 weeks after starting the therapy). If assigned to receive TF-CBT, participants will take part in 12 to 16 weekly therapy sessions and five study visits (before therapy, and 6-week, 10-week, 20-weeks, and 30-weeks after starting the therapy). The purpose of the study visits for a 30-week time period is to better understand who they are as a person and their current mental health symptoms and diagnoses. All therapy and study visits can be completed remotely or in person, per your preference. Individuals who are 18 can participate without caregiver permission; individuals aged 12 to 17 can only participate with caregiver permission. Our goal is to find the best way to provide effective PTSD treatment for young people that can be delivered in real-world pediatric primary care settings, so that ultimately more people can get the help they need after traumatic experiences.

The investigational varicella vaccine (hereafter referred to as VNS vaccine) is a new
candidate varicella vaccine derived from the Oka strain. The main rationale for the
development of VNS vaccine is to provide an additional alternative varicella vaccine as an advantage from a public health perspective to prevent varicella disease

This study focuses on adolescents who experience both substance use problems and post-traumatic stress disorder (PTSD), which often occur together and can seriously impact mental health, school performance, and relationships if left untreated. The goal is to evaluate a trauma-focused treatment called Concurrent Treatment of PTSD and Substance Use Disorders for Adolescents (COPE-A), which is designed to address both conditions at the same time. Earlier pilot studies showed that COPE-A is safe, feasible, and effective in reducing substance use and PTSD symptoms compared to a supportive counseling approach.

In this larger study, 120 adolescents from across the U.S. will receive treatment through telehealth. Researchers will compare COPE-A to person-centered therapy to see which leads to greater improvements in substance use and PTSD symptoms. The study will also examine effects on depression, HIV risk behaviors, relationships, and overall quality of life, while using brief daily surveys to track changes over time.

Written Exposure Therapy (WET) is a five-session mental health therapy for post-traumatic stress disorder (PTSD). Research shows that it works as well as longer treatments for PTSD among people over 18, even though it requires fewer sessions than other PTSD therapies. However, WET has not been adapted and tested via telehealth with people aged 12 to 18. Our study aims to see how WET can be adapted to meet the needs of people aged 12 to 18 who have experienced trauma and currently have PTSD symptoms. To adapt WET for this age group, first we will talk with PTSD experts and people aged 12 to 18 to learn what changes might make WET more suitable for young people. We'll also deliver WET via telehealth to five people aged 12 to 18 following the manual as it is written for people over age 18 to see what needs adjusting. In the next part of the study, we will offer the adapted version of WET via telehealth to 20 people aged 12 to 18 in our MUSC integrated pediatric primary care clinic. People aged 12 to 18 will take part in five to seven weekly online therapy sessions and three virtual study visits (before therapy, after therapy, and one month later) to better understand who they are as a person and their current mental health symptoms and diagnoses. Individuals who are 18 can participate without caregiver permission; individuals aged 12 to 17 can only participate with caregiver permission. Our goal is to find the best way to provide effective PTSD treatment for young people that can be delivered in real-world pediatric primary care settings, so that ultimately more people can get the help they need after traumatic experiences.

A germ (bacterium) called meningococcus, or Neisseria meningitidis, can cause several serious diseases, including meningitis and blood infection. Meningitis affects the brain and spinal cord. It can cause hearing loss, seizures, learning and behavior problems, severe brain damage and even death. Meningitis can happen to anyone but is more common in teenagers and young children, including babies. This research study will help us learn about vaccines that protect against diseases caused by different types of meningococcus germs: types A, B, C, W, Y.

This study is being conducted to learn more about the safety and immune response of the study vaccine MenABCWY when 2 doses are given 24 months apart (0,24-month schedule) or 48 months apart (0,48-month schedule). The study will be conducted in healthy adolescents from 11 to 14 years of age.

This study aims to look at injury rates experienced during a club travel volleyball season as correlated with self reported scores on the GRIT scale, Brief Resiliency Scale (BRS), and Athlete Burnout Questionnaire (ABQ) in male and female high school age volleyball players. The GRIT asks questions about passion and perseverance to achieve goals.
The BRS asks questions about resiliency after stress.
The ABQ asks questions to understand the determinants and consequences of athlete burnout. Completion of these surveys will take approximately 20 minutes.

Upon receiving and compiling all survey data, appropriate statistical analysis will be performed to assess for trends in the development of injuries and inform best practice on training.

The purpose of this study is to test whether a mobile app, the Digital Wellness Nurse (DWN), can help families with weight problems lead healthier lifestyles. Participants in this study will receive education and tips on physical activity and healthy eating through weekly videos and online meetings with a community health worker (CHW) via the DWN app. The meetings with the CHW will take place once a week for 12 weeks. During these meetings, adolescents and their caregiver will set weekly goals and have the chance to earn incentives for meeting them. While in the study, participants will be asked to wear a Fitbit to track physical activity and to complete a monthly survey about eating and physical activity habits. At the end of the study, participants will be asked to participate in a focus group and talk about their experiences with the app and the study. Participation in this study may improve physical well-being, but that cannot be guaranteed.

This is a Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multiple dose level study to investigate the efficacy and safety of subcutaneous injections of amlitelimab in participants aged 12 years and older with moderate-to-severe AD who are on background topical corticosteroids or calcineurin inhibitors and have had an inadequate response to prior biologic or oral JAKi therapy. There will be up to 13 visits including up to a 4-week screening period, a 36 week treatment period, and a post-treatment safety follow up period or a long-term Safety Study for 16 weeks. Subjects will be randomized in a 1:1:1 ratio to the following study arms: amlitelimab Q4W, amlitelimab Q12W, and placebo Q4W.